Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3273 | 2019 |
Immunotherapy in colorectal cancer: rationale, challenges and potential K Ganesh, ZK Stadler, A Cercek, RB Mendelsohn, J Shia, NH Segal, ... Nature reviews Gastroenterology & hepatology 16 (6), 361-375, 2019 | 1336 | 2019 |
PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 942 | 2022 |
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 718 | 2018 |
Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 586 | 2019 |
Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 534 | 2019 |
Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 534 | 2018 |
Adoption of total neoadjuvant therapy for locally advanced rectal cancer A Cercek, CSD Roxburgh, P Strombom, JJ Smith, LKF Temple, GM Nash, ... JAMA oncology 4 (6), e180071-e180071, 2018 | 530 | 2018 |
Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 476 | 2020 |
Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ... Jama 318 (9), 825-835, 2017 | 474 | 2017 |
Discovery of common and rare genetic risk variants for colorectal cancer JR Huyghe, SA Bien, TA Harrison, HM Kang, S Chen, SL Schmit, ... Nature genetics 51 (1), 76-87, 2019 | 463 | 2019 |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 429 | 2017 |
Tumour lineage shapes BRCA-mediated phenotypes P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ... Nature 571 (7766), 576-579, 2019 | 363 | 2019 |
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer DJ Gallagher, MM Gaudet, P Pal, T Kirchhoff, L Balistreri, K Vora, J Bhatia, ... Clinical cancer research 16 (7), 2115-2121, 2010 | 360 | 2010 |
Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations ZI Hu, J Shia, ZK Stadler, AM Varghese, M Capanu, E Salo-Mullen, ... Clinical Cancer Research 24 (6), 1326-1336, 2018 | 359 | 2018 |
Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation EM O’Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ... Journal of Clinical Oncology 38 (13), 1378-1388, 2020 | 339 | 2020 |
Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data S Middha, L Zhang, K Nafa, G Jayakumaran, D Wong, HR Kim, ... JCO precision oncology 1, 1-17, 2017 | 338 | 2017 |
Counselling framework for moderate-penetrance cancer-susceptibility mutations N Tung, SM Domchek, Z Stadler, KL Nathanson, F Couch, JE Garber, ... Nature reviews Clinical oncology 13 (9), 581-588, 2016 | 337 | 2016 |
Genetic predictors of response to systemic therapy in esophagogastric cancer YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ... Cancer discovery 8 (1), 49-58, 2018 | 335 | 2018 |
Germline variants in targeted tumor sequencing using matched normal DNA KA Schrader, DT Cheng, V Joseph, M Prasad, M Walsh, A Zehir, A Ni, ... JAMA oncology 2 (1), 104-111, 2016 | 330 | 2016 |